Editor's note

This ExpertREACT article was originally published on 18 November 2008. Clinical data and epidemiological figures described reflect the state of knowledge at that date.

C.diff: worse than MRSA?

Clostridium difficile (C.diff) is a Gram-positive bacterium that can harmlessly colonise the human gut, but in patients who are predominantly older than 65 years and have undergone intensive antibiotic therapy - typically residing in hospital or long-term care facilities - it can cause disease (CDI) through toxin production that drives colitis and inflammation. Colonisation rates in vulnerable patients in these settings reached 30-40% as normal gut flora was diminished. Outcomes ranged from mild diarrhoea to severe-complicated disease with fever, tachycardia and pseudomembranous colitis. Mortality rates were typically 6-30%, rising to 35-50% in patients with toxic megacolon requiring surgical colectomy. Some experts noted that in their institutions CDI was becoming a greater challenge than MRSA, particularly due to the emergence of ribotype 027/NAP1 strains associated with higher severity.

A new APIC (Association for Professionals in Infection Control) survey suggested that CDI colonisation and incidence in US hospitals was higher than previously reported - a finding that strengthened the case for better surveillance and novel treatment and prevention approaches. In the EU, mandatory CDI reporting existed only in the UK, Belgium and Ireland, with countries such as Spain and Italy lacking any notifiable disease classification for C.diff. A pan-European surveillance study was planned for 2009 to begin providing more systematic data. VacZine Analytics had been tracking C.diff vaccine development - including Sanofi's ACAM-C-DIFF programme acquired with Acambis - as a potential novel intervention for high-risk populations.

CDI mortality in complicated cases
35-50%
Mortality in C.diff patients with toxic megacolon requiring colectomy; typical CDI mortality 6-30% across hospitalised patients

OPT-80: a new treatment option on the horizon

The positive news in the article came from Optimer Pharmaceuticals, which published Phase III data for OPT-80 (fidaxomicin) showing that the rate of CDI recurrence after treatment was lower than with the gold-standard oral vancomycin. High recurrence rates - typically 20-25% with existing treatments - were one of the most clinically challenging aspects of CDI management, and reducing recurrence was a primary endpoint of high value to clinicians, hospitals and payers. OPT-80's Phase III results represented the first meaningful positive clinical data from a new CDI treatment class in many years and were expected to support a regulatory filing. From VacZine Analytics' perspective, the CDI therapeutic and preventive landscape was entering an important phase of commercial activity.